1. A pharmaceutical product containing the first active ingredient, which is (1R, 3aS, 3bS, 10aR, 10bS, 11S, 12aS) -1 - {[(cyanomethyl) sulfanyl] carbonyl} -7- (4-fluorophenyl) -11 -hydroxy-10a, 12a-dimethyl-1,2,3,3a, 3b, 4,5,7,10,10a, 10b, 11,12,12a-tetradecahydrocyclopenta [5,6] naphtho [1,2-f ] indazol-1-ylfuran-2-carboxylate； a second active ingredient selected from a β-adrenergic receptor agonist, a double β-adrenergic receptor agonist / M receptor antagonist, a muscarinic antagonist, a p38 kinase inhibitor, a neutrophil elastase inhibitor, a phosphodieste inhibitor PD4 inhibitor IKK2 or a non-steroidal glucocorticoid receptor agonist and possibly one or more pharmaceutically acceptable excipients. 2. The pharmaceutical product according to claim 1, which is in a form suitable for administration by inhalation. A pharmaceutical product containing a preparation of a first active ingredient that is (1R, 3aS, 3bS, 10aR, 10bS, 11S, 12aS) -1 - {[(cyanomethyl) sulfanyl] carbonyl} -7- (4-fluorophenyl) -11- hydroxy-10a, 12a-dimethyl-1,2,3,3a, 3b, 4,5,7,10,10a, 10b, 11,12,12a-tetradecahydrocyclopenta [5,6] naphtho [1,2-1] indazol-1-ylfuran-2-carboxylate, and a second active ingredient preparation selected from a β-adrenergic receptor agonist, a double β-adrenergic receptor agonist / M-receptor antagonist, a muscarinic antagonist, a p38 kinase inhibitor, a neutrophilic elastase inhibitor, a phosphodieste inhibitor times PDE4, kinase IKK2 inhibitor or non-steroidal glucocorticoid receptor agonist, wherein said drugs are intended for simultaneous, sequential or separate administration to a patient in need etom.4. The pharmaceutical product according to claim 3, where each of the drugs of the first and second act1. Фармацевтический продукт, содержащий первый активный ингредиент, который представляет собой (1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(цианометил)сульфанил]карбонил}-7-(4-фторфенил)-11-гидрокси-10а,12а-диметил-1,2,3,3а,3b,4,5,7,10,10а,10b,11,12,12а-тетрадекагидроциклопе
